DIGITAL-VAULT-SERVICES
15.4.2024 09:01:30 CEST | Business Wire | Press release
Digital Vault Services:
- Siemens chooses Digital Vault Services (DVS) for guarantee digitization.
- Collaboration with Digital Vault Services reflects Siemens commitment to innovation and efficiency.
- DVS’s Guarantee Vault Platform enables Siemens to optimize workflow efficiency and enhance security in guarantee management.
Siemens, a technology company focused on industry, infrastructure, transport, and healthcare, chooses Digital Vault Services for guarantee digitization, reflecting its dedication to innovation and efficiency. Through the integration of Digital Vault Services' innovative Guarantee Vault Platform (GVP), Siemens propels its digital transformation journey within its Guarantee Business, leveraging technology to optimize operations and enhance customer satisfaction.
The adoption of the Guarantee Vault will empower Siemens for streamlined and digitized guarantee processes. With GVP integrated into its operations, Siemens will benefit from GVP’s unchallenged capabilities to seamlessly connect to the entire guarantee ecosystem including all bank and insurance partners.
Gerhard Heubeck, Global Head Trade Finance Advisory at Siemens, commented, “We are pleased to announce our partnership with Digital Vault Services. As an active member of the working group, we have always been convinced of GVP's capabilities to significantly improve our collaboration and communication with our financial partners and to eliminate time-consuming, manual and paper-based processes. By leveraging GVP's innovative features, we can now engage in efficient, fast, and paperless interactions, while fully digitizing the end-to-end process from our organization through our financial partners to our valued customers. “
"We are thrilled to collaborate with Siemens, a key member of the working group that contributed to the development of our Guarantee Vault Platform," said Ludger Janßen, Co-CEO of Digital Vault Services. "Siemens commitment to innovation aligns perfectly with our mission to digitize the entire guarantee ecosystem and helps with the digital transformation of the financial industry. Together, we will drive significant advancements in guarantee processing efficiency and security."
Jaime Gimeno, Co-CEO of Digital Vault Services added: "With digital guarantees issued, secured and safekept on Guarantee Vault, Siemens and its customers are well positioned to achieve maximum efficiency and transparency. We do all this using best in class technology secured to ISO 27001 standards to keep our customers safe. We welcome Siemens to our network and look forward to working with them on their digitization journey."
About Digital Vault Services
Digital Vault Services GmbH revolutionizes the guarantee journey with its Guarantee Vault, boosting complete digitization. This solution offers a seamless, paperless experience, transforming the guarantee ecosystem end to end. Applicants can request all types of guarantees globally within one central tool, while banks and insurers securely issue and store guarantees. Beneficiaries enjoy seamless interaction and can manage and access the guarantees anytime. Innovative features such as beneficiary read confirmation and pre-approved wording libraries enhance processing speed, transparency, and efficiency. With top-tier security standards and API integration for seamless connectivity, DVS ensures a robust solution for all guarantee- business needs.
Founded in 2018 through collaboration with 16 industry participants, banks and insurers, Digital Vault Services has rapidly evolved. Since its launch in 2021, Guarantee Vault has gained strong traction in Germany and is now expanding into other European markets, including the Nordic countries, where future presence has already been announced. The company’s headquarters are located in Munich, Germany.
About Siemens
Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, transport, and healthcare. From more resource-efficient factories, resilient supply chains, and smarter buildings and grids, to cleaner and more comfortable transportation as well as advanced healthcare, the company creates technology with purpose adding real value for customers. By combining the real and the digital worlds, Siemens empowers its customers to transform their industries and markets, helping them to transform the everyday for billions of people. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a globally leading medical technology provider shaping the future of healthcare. In fiscal 2023, which ended on September 30, 2023, the Siemens Group generated revenue of €77.8 billion and net income of €8.5 billion. As of September 30, 2023, the company employed around 320,000 people worldwide. Further information is available on the Internet at www.siemens.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240412273459/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom